IWC
KYTX icon

Integrated Wealth Concepts’s Kyverna Therapeutics KYTX Stock Holding History

Integrated Wealth Concepts’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$356 Buy
+40
New +$355 ﹤0.01% 5692

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Integrated Wealth Concepts's KYTX Position: Q2 2026 in Review

Integrated Wealth Concepts opened a new position in Kyverna Therapeutics (KYTX) in Q2 2026: 40 shares worth $356. The stake represents ﹤0.01% of the portfolio and ranks #5692 among its holdings.

120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Integrated Wealth Concepts held 40 shares of Kyverna Therapeutics worth $356 as of Q2 2026.
  • Kyverna Therapeutics was a new Integrated Wealth Concepts position in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of Integrated Wealth Concepts's portfolio in Q2 2026, its #5692 holding.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Integrated Wealth Concepts's 13F filing for Q2 2026, filed 12 Aug 2026.